<![CDATA[EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma]]>

Data ReadoutIberdomideDaratumumabDexamethasoneNeutral

AI Analysis

Summary

Dr. Joshua Richter reviews the EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma. The article provides a clinical overview without reporting trial outcomes or specific efficacy data.

Clinical Trial Data

Importance:5/10

Sentiment:

0.00

multiple_myelomaEXCALIBER-RRMMcombination_therapyrelapsed_refractory

Related Companies

$BMY

Read the original article

Published by Cancer Network on September 30, 2026 4:05 PM

Read Original